Page 36 - 《中国药科大学学报》2026年第2期

162 学报 Journal of China Pharmaceutical University 2026, 57(2): 155 − 162 第 57 卷

Spliceostatin A interaction with SF3B limits U1 snRNP avail- JAK 2 V617F-driven myeloproliferative neoplasm[J]. Blood Can-
ability and causes premature cleavage and polyadenylation[J]. cer J, 2023, 13(1): 171.
Cell Chem Biol, 2021, 28(9): 1356-1365. e4. [45] Rogalska ME, Mancini E, Bonnal S, et al. Transcriptome-wide
[29] Damianov A, Lin CH, Zhang J, et al. Cancer-associated SF3B1 splicing network reveals specialized regulatory functions of the
mutation K700E causes widespread changes in U2/branchpoint core spliceosome[J]. Science, 2024, 386(6721): 551-560.
recognition without altering splicing[J]. bioRxiv, 2024: 2024.11. [46] Wu HJ, Lima WF, Zhang H, et al. Determination of the role of
18.624191. the human RNase H1 in the pharmacology of DNA-like anti-
[30] Zhang C, Shen L, Yuan W, et al. Loss of SRSF2 triggers hepat- sense drugs[J]. J Biol Chem, 2004, 279(17): 17181-17189.
ic progenitor cell activation and tumor development in mice[J]. [47] Crooke ST. Molecular mechanisms of antisense oligonu-
Commun Biol, 2020, 3(1): 210. cleotides[J]. Nucleic Acid Ther, 2017, 27(2): 70-77.
[31] Kurosaki T, Popp MW, Maquat LE. Quality and quantity con- [48] Ma WK, Voss DM, Scharner J, et al. ASO-based PKM splice-
trol of gene expression by nonsense-mediated mRNA decay[J]. switching therapy inhibits hepatocellular carcinoma growth[J].
Nat Rev Mol Cell Biol, 2019, 20(7): 406-420. Cancer Res, 2022, 82(5): 900-915.
[32] Chen CH, Zhou PL, Zhang ZZ, et al. U2AF1 mutation con- [49] Reilley MJ, McCoon P, Cook C, et al. STAT3 antisense
nects DNA damage to the alternative splicing of RAD51 in lung oligonucleotide AZD9150 in a subset of patients with heavily
adenocarcinomas[J]. Clin Exp Pharmacol Physiol, 2022, 49(7): pretreated lymphoma: results of a phase 1b trial[J]. J Im-
740-747. munother Cancer, 2018, 6(1): 119.
[33] Esfahani MS, Lee LJ, Jeon YJ, et al. Functional significance of [50] Odate S, Veschi V, Yan S, et al. Inhibition of STAT3 with the
U2AF1 S34F mutations in lung adenocarcinomas[J]. Nat Com- generation 2.5 antisense oligonucleotide, AZD9150, decreases
mun, 2019, 10(1): 5712. neuroblastoma tumorigenicity and increases
[34] Hsu TY, Simon LM, Neill NJ, et al. The spliceosome is a thera- chemosensitivity[J]. Clin Cancer Res, 2017, 23(7): 1771-1784.
peutic vulnerability in MYC-driven cancer[J]. Nature, 2015, [51] Nishina T, Fujita T, Yoshizuka N, et al. Safety, tolerability,
525(7569): 384-388. pharmacokinetics and preliminary antitumour activity of an an-
[35] Wang ZX, Wang SR, Qin JC, et al. Splicing factor BUD31 pro- tisense oligonucleotide targeting STAT3 (danvatirsen) as
motes ovarian cancer progression through sustaining the expres- monotherapy and in combination with durvalumab in Japanese
sion of anti-apoptotic BCL2L12[J]. Nat Commun, 2022, 13(1): patients with advanced solid malignancies: a phase 1 study[J].
6246. BMJ Open, 2022, 12(10): e055718.
[36] Xu N, Ren YP, Bao YF, et al. PUF 6 0 promotes cell cycle and [52] Miao C M, Wu Q P, Zhang L Y, et al. Research progress of al-
lung cancer progression by regulating alternative splicing of ternative splicing in tumor chemotherapy resistance[J]. Journal
CDC25C[J]. Cell Rep, 2023, 42(9): 113041. of Pharmaceutical Research, 2023, 42(12): 1016-1021.
[37] Zheng JY, Wu SS, Tang M, et al. USP39 promotes hepatocellu- [53] Buxade M, Parra-Palau JL, Proud CG. The Mnks: MAP kinase-
lar carcinogenesis through regulating alternative splicing in co- interacting kinases (MAP kinase signal-integrating kinases)[J].
operation with SRSF6/HNRNPC[J]. Cell Death Dis, 2023, Front Biosci, 2008, 13: 5359-5373.
14(10): 670. [54] Xu QR, Liu X, Liu ZK, et al. microRNA-1296 inhibits metasta-
[38] Zhu XL, Ma JL, Lu MY, et al. The deubiquitinase USP39 pro- sis and epithelial-mesenchymal transition of hepatocellular car-
motes esophageal squamous cell carcinoma malignancy as a cinoma by targeting SRPK1-mediated PI3K/AKT pathway[J].
splicing factor[J]. Genes (Basel), 2022, 13(5): 819. Mol Cancer, 2017, 16(1): 103.
[39] Zhang Q, Ai YX, Abdel-Wahab O. Molecular impact of muta- [55] Wang C, Zhou ZH, Subhramanyam CS, et al. SRPK1 acetyla-
tions in RNA splicing factors in cancer[J]. Mol Cell, 2024, tion modulates alternative splicing to regulate cisplatin resis-
84(19): 3667-3680. tance in breast cancer cells[J]. Commun Biol, 2020, 3(1): 268.
[40] Brandi G, Deserti M, Palloni A, et al. Intrahepatic cholangiocar- [56] Lu SX, De Neef E, Thomas JD, et al. Pharmacologic modula-
cinoma development in a patient with a novel BAP1 germline tion of RNA splicing enhances anti-tumor immunity[J]. Cell,
mutation and low exposure to asbestos[J]. Cancer Genet, 2020, 2021, 184(15): 4032-4047. e31.
248/249: 57-62. [57] Eram MS, Shen YD, Szewczyk M, et al. A potent, selective,
[41] Xiong X, Ke XR, Wang L, et al. Splice variant of growth hor- and cell-active inhibitor of human type I protein arginine
mone-releasing hormone receptor drives esophageal squamous methyltransferases[J]. ACS Chem Biol, 2016, 11(3): 772-781.
cell carcinoma conferring a therapeutic target[J]. Proc Natl [58] Dioken DN, Ozgul I, Yilmazbilek I, et al. An alternatively
Acad Sci USA, 2020, 117(12): 6726-6732. spliced PD-L1 isoform PD-L1∆3, and PD-L2 expression in
[42] Anczukow O, Allain FH, Angarola BL, et al. Steering research breast cancers: implications for eligibility scoring and im-
on mRNA splicing in cancer towards clinical translation[J]. Nat munotherapy response[J]. Cancer Immunol Immunother, 2023,
Rev Cancer, 2024, 24(12): 887-905. 72(12): 4065-4075.
[43] Bewersdorf JP, Stahl M, Taylor J, et al. E7820, an anti-cancer [59] Zhao C, Zhao JW, Zhang YH, et al. PTBP3 mediates IL-18 ex-
sulfonamide, degrades RBM39 in patients with splicing factor on skipping to promote immune escape in gallbladder cancer[J].
mutant myeloid malignancies: a phase II clinical trial[J]. Adv Sci (Weinh), 2024, 11(38): e2406633.
Leukemia, 2023, 37(12): 2512-2516. [60] Nützinger J, Lee JB, Li Low J, et al. Management of HER2 al-
[44] Yang Y, Abbas S, Sayem MA, et al. SRSF2 mutation reduces terations in non-small cell lung cancer–The past, present, and
polycythemia and impairs hematopoietic progenitor functions in future[J]. Lung Cancer, 2023, 186: 107385.